Key result
Liposome-conjugated SLex-oligosaccharide significantly attenuated myocardial necrosis compared to vehicle (8.6% vs 29.5% of area-at-risk, P<0.01) in a feline model of ischaemia-reperfusion injury.
Why the study?
Does liposome-conjugated SLex-oligosaccharide reduce myocardial necrosis and preserve endothelial function in a feline model of myocardial ischemia and reperfusion injury?
Population
Feline model of myocardial ischemia and reperfusion injury in vivo, and an in vitro system of neutrophil…
Comparison
Liposome-conjugated sialyl… vs Vehicle (liposome alone)
Design
Preclinical
Follow-up
270 minutes of reperfusion
Authors
Loading...
Hypothesis-generating for selectin inhibition in reperfusion injury; leaves open translation to human myocardial infarction.
Does liposome-conjugated SLex-oligosaccharide reduce myocardial necrosis and preserve endothelial function in a feline model of myocardial ischemia and reperfusion injury?
Absolute Event Rate: 8.6% vs 29.5%
p-value: p=<0.01
Liposome-conjugated SLex-oligosaccharide attenuates myocardial necrosis and preserves coronary endothelial function following ischemia/reperfusion injury in a feline model by inhibiting PMN-endothelial interaction.
Murohara et al. (1995) studied Myocardial ischaemia and reperfusion injury. Liposome-conjugated sialyl Lewisx-oligosaccharide (Lipo-SLex) vs. Vehicle (liposome alone) was evaluated on Myocardial necrosis (% of area-at-risk) (p=<0.01). Liposome-conjugated SLex-oligosaccharide significantly attenuated myocardial necrosis compared to vehicle (8.6% vs 29.5% of area-at-risk, P<0.01) in a feline model of ischaemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: